In this study, we examined the effect of intrathecal (IT) gabapentin, administered before and after the injection of formalin into the rat hindpaw, on pain behavior and hemodynamics. Formalin evoked a biphasic flinching behavior and hypertension. IT gabapentin administered 10 min before formalin produced a dose-dependent reduction of the Phase 2, but not Phase 1, flinching and cardiovascular response. In contrast, IT gabapentin administered 9 min after formalin had no effect on either phase of flinching. IT d-serine (100 g) administered 10 min before IT gabapentin reversed the Phase 2 effect of gabapentin. IT gabapentin did not affect the thermal escape latency or the baseline cardiovascular measures even at the largest dose (300 g). These results indicate that the spinal effect of gabapentin reduces the somatosympathetic reflex and somatosensory response to tissue injury without an accompanying effect on acute nociception or resting sympathetic outflow. Implications: After tissue injury, there is an enhanced pain behavior and cardiovascular response, representing a facilitated state of spinal processing. Spinally delivered gabapentin had no evident effect on resting heart rate or blood pressure, but it attenuated the enhanced pain behavior and cardiovascular response otherwise produced by injury.
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(Anesth Analg 1999;89:434 -9) G abapentin is an anticonvulsant that was synthesized as a structural analog to ␥-aminobutyric acid (GABA). Studies of the activity profile of gabapentin indicate that intrathecally (IT) and systemically administered gabapentin reverses: 1) tactile allodynia in the Chung model of neuropathy (1); 2) thermal hyperalgesia in the Bennett model of neuropathy (2); 3) thermal hyperalgesia induced by thermal injury to the paw (3); and 4) the second phase of the formalin test (4,5) after systemic or IT administration. There is no change, however, in the response latency after gabapentin administration in models with acute noxious stimuli, such as the hot plate or tail flick (6,7). The above observations suggest that gabapentin alters spinal mechanisms of facilitated processing.
The injection of formalin into the hindpaw of the rat evokes not only a biphasic flinching of the injected paw (a somatomotor response), but also an associated somatosympathetic reflex (increased blood pressure) (8) . There is no information on the effects of spinal gabapentin on the somatosympathetic response evoked by pain. In the present study, we evaluated the characteristics of the spinal action of gabapentin on the somatomotor response (flinching behavior) and cardiovascular response to the injection of formalin into the paw when gabapentin was injected before and after the formalin stimulus.
Methods
All experiments were performed under a protocol approved by the Institutional Animal Care Committee of the University of California, San Diego. Male SpragueDawley rats (300 -325 g) were housed individually on a 12-h day/night cycle. Animals were allowed free access to food and water. For the IT administration of the drug, IT catheters were implanted under halothane anesthesia using a technique described previously (9) . Briefly, rats were anesthetized with halothane/O 2 /air. Their heads were placed in a stereotaxic holder. An incision was made along the dorsum of the skull, and dura mater was exposed by blunt dissection. The dura was incised, and a polyethylene (PE-10) catheter was advanced 8.5 cm caudally to end at the lumbar enlargement. The external catheter was tunneled under the skin and exited at the top of the head. The skin was closed with 3-0 silk sutures. Rats showing neurologic deficits postoperatively were killed immediately by CO 2 inhalation. After implantation of the IT catheters, rats were housed in individual cages and allowed to recover for 4 -5 days. They were then assigned to the study.
Gabapentin (1-[aminomethyl] cyclohexanacetic acid; Neurontin; Parke-Davis, Ann Arbor, MI) and d-serine (Sigma Chemical, St. Louis, MO) were used in this study. Drugs were dissolved in physiologic saline and injected in a 10-L solution, followed by an additional 10 L of saline to flush the catheter.
For hemodynamic measurement, rats were anesthetized under a halothane/O 2 /air mixture, and a PE-50 catheter was inserted into the tail artery. The rats were then placed in a restraint cylinder, and their arterial lines were connected to a pressure transducer that led into a polygraph for continuous recording of mean arterial blood pressure (MAP) and heart rate (HR).
For the formalin test, 50 L of 5% formalin solution was injected subcutaneously into the plantar surface of the left hindpaw with a 30-gauge needle. The formalin injection produced a characteristic flinching/ shaking of the injected paw. Pain-related behavior was therefore quantified by periodically counting the incidences of spontaneous flinching/shaking of the injected paw. The number of flinches was counted for 1-min periods at 1 and 5 min and at 5-min intervals from 10 to 60 min. After the formalin injection into the paw, two phases of spontaneous flinching were observed. Phases 1 and 2 were defined as 0 -9 or 10 -60 min after the formalin injection, respectively.
The nociceptive response was determined by exposing the plantar surface of the hindpaw to radiant heat using a modified Hargreaves-type thermal testing device (10, 11) . In brief, rats were placed in individual enclosures on a glass surface at 30°C. The radiant thermal stimulus beneath the glass plate was positioned directly under either paw. Activation of the stimulus simultaneously activated a timer. Both bulb and timer were turned off by paw withdrawal or after 20 s (cutoff time). After acclimation for 20 -30 min, a measurement was taken for each hindpaw to determine an average baseline latency. The mean of the response latencies from each paw was taken as the latency.
After IT catheter placement, the rats underwent tail artery cannulation. After a 30-to 40-min adaptation, baseline MAP and HR were measured. Two drug injection paradigms were used. For gabapentin pretreatment, IT gabapentin was administered 10 min before the formalin injection. The time course and dose-response effects of gabapentin on flinching, MAP, and HR were determined. For gabapentin posttreatment, IT gabapentin was injected 9 min after the formalin injection. The time course of changes in flinching, MAP, and HR were determined.
To further examine the possible relationship between the actions of gabapentin and the N-methyl-daspartate (NMDA) receptor complex, IT d-serine (100 g) was administered 10 min before the IT gabapentin (300 g) injection, and formalin was injected 10 min later.
To evaluate the IT effect of gabapentin on acute noxious stimuli, the thermal escape response latency was measured 15, 30, 60, 90, and 120 min after injection.
All data are presented as means Ϯ sem. The timeresponse data are presented as the number of flinches or change from the baseline MAP and HR. Doseresponse data are presented as the sum of flinches or the sum of percent change of MAP and HR in two phases. Dose-response data were analyzed by using the Jonckheere test. The effect of IT d-serine and the comparison of gabapentin pretreatment and posttreatment were assessed by one-way analysis of variance (ANOVA) with a Fisher's protected least significant difference for multiple comparisons. Baseline MAP and HR were compared by using one-way ANOVA. The cardiovascular effects of IT d-serine and gabapentin alone were examined by using a paired t-test or repeated-measures ANOVA. In all tests, statistical significance was considered at a critical value of P Ͻ 0.05.
Results
The latency of the thermally evoked escape response was not affected by the IT injection of gabapentin. Thus, the baseline escape latency was 4.9 Ϯ 0.2, and the maximal post-IT injection escape latency was 5.1 Ϯ 0.2 (n ϭ 6). No change was seen in the pinna, corneal reflex, and motor function after IT gabapentin administration. Some rats showed decreased spontaneous activity indicative of minimal sedation at 300 g of gabapentin.
The baseline MAP and HR were 103 Ϯ 1 mm Hg and 422 Ϯ 3 bpm, respectively (n ϭ 55). The baseline MAP and HR in the several treatment groups did not differ statistically (P Ͼ 0.1).
Formalin injection into the hindpaw resulted in a biphasic incidence (Phase 1 and Phase 2) of flinching of the injected paw and corresponding biphasic hypertension and tachycardia.
IT gabapentin did not affect the baseline MAP and HR (Fig. 1) . Gabapentin, administered IT 10 min before formalin injection, did not alter the flinching and cardiovascular response otherwise noted during Phase 1 (Fig. 2) . During Phase 2, IT gabapentin produced a dose-dependent reduction in flinching and the magnitude of the MAP and HR response (P Ͻ 0.05) (Fig. 3) .
IT d-serine (100 g) had no effect on the baseline cardiovascular measures. Administered 10 min before IT gabapentin (300 g), this dose antagonized the suppression of flinching otherwise produced by IT gabapentin (P Ͻ 0.05) (Fig. 4) . The IT gabapentin's suppression of the formalin-evoked MAP and HR response was also numerically diminished, but this reversal did not reach statistical significance (P Ͼ 0.1).
As indicated, the preformalin injection of IT gabapentin resulted in a significant reduction in Phase 2 flinching behavior. In contrast to the effects of pretreatment, the IT delivery of gabapentin (300 g) 9 min after formalin injection had no effect on the flinching behavior otherwise observed during the second phase of the formalin test (Fig. 5) .
Discussion
The subcutaneous injection of formalin into the paw evokes an initial barrage of nerve activity, followed by a low level of persistent discharge in small afferents (12) . Behaviorally, this injection evokes an initial intense phase of flinching, followed by an interval of quiescence, then a second phase of intense flinching. Phase 1 is believed to correspond to the high level of activity in the primary afferent, whereas Phase 2 seems to result from the continuous low level of small afferent input, together with a facilitated state of spinal processing. The afferent input generated by formalin is believed to release excitatory amino acids (glutamate) and peptides (such as substance P), which, through NMDA and NK1 receptors, initiate a cascade. The resulting cascade is thought to underlie a state of facilitated processing (13) . Not surprisingly, this facilitated processing (evidenced in the behavioral response of flinching and licking of the injected paw) also serves to drive a somatosympathetic response, e.g., increased MAP and HR. This cardiovascular response displays a biphasic time course that parallels the observed flinching behavior (8) .
The spinal action of gabapentin has little effect on acute nociceptive processing, but it attenuates the facilitated component of the response evoked by persistent small afferent input. Thus, the thermal hyperalgesia or tactile allodynia induced by local tissue injury, antibodies, nerve injury, and the IT delivery of substance P or NMDA are reversed by IT or systemic doses of gabapentin that have no effect on acute thresholds or motor function (3, 14, 15) . The systemic or IT delivery of gabapentin reduces the second phase of the formalin test (4, 5) . As in other models of hyperalgesia, the IT dose of gabapentin necessary to reverse these effects is several orders of magnitude less than that required systemically, emphasizing a likely spinal site of action (17) .
At the largest dose of gabapentin, several rats displayed some sign of a modest reduction in spontaneous activity. We do not think that this effect accounted for the observed antihyperalgesic effects. First, even at the largest doses, there was no change in other indices of sedation (e.g., cornea and pinna blockade). Second, although there was a significant obtundation of the behavioral response to the formalin, the resting blood pressure was not significantly altered after the largest dose, which again suggests no general sedative effect.
The present study extends previous work by showing that these drug actions are observed with respect to the small afferent-evoked somatosympathetic reflex. Importantly, these actions on the evoked changes in MAP were noted in the absence of any significant effect on either resting MAP or HR. A similar tolerability has been observed in humans (16) after systemic delivery. The absence of an effect on the Phase 1 blood pressure response, along with the lack of posttreatment effect on Phase 2 MAP changes, further emphasizes that the gabapentin effect is not a general suppressor of autonomic activity. These observations thus suggest that gabapentin does not produce a significant alteration of resting or acutely evoked autonomic outflow in the unanesthetized rat.
In contrast to pretreatment with gabapentin, posttreatment with gabapentin had little effect on the flinching or MAP response during Phase 2. This temporal profile of activity resembles that observed with IT NK1 or NMDA receptor antagonists (17,18). The Figure 3 . Dose-response curve of intrathecal gabapentin for the flinching (top), mean arterial pressure (MAP), and heart rate (HR) during Phase 1 and Phase 2 on the formalin test. Responses of both phases are presented as the sum of flinches or the sum of percent change of MAP and HR. Intrathecal gabapentin had no effect on Phase 1, whereas it produced a dose-dependent reduction in flinching and the magnitude of the cardiovascular response. C ϭ control. Each dose represents the mean Ϯ sem for five rats. *P Ͻ 0.05. interpretation of these results is that gabapentin blocks the initiation of a cascade required for the facilitated state but does not reverse the process once initiated. We believe that the facilitatory cascade evoked by a brief injurious stimulus has a short temporal half-life. In the clinical setting, the facilitation induced by a persistent injury would be continually reinitiated. Thus, blocking the initial step of the cascade would show the antihyperalgesic action after a delay defined by the acute duration of the facilitated state.
The mechanism of gabapentin action is not certain. Gabapentin does not interact with either GABA A or GABA B receptors, and although it can enhance GABA synthesis and release (19) , in studies of the Chung model of neuropathy, the spinal delivery of either GABA A or GABA B receptor antagonists had no effect on the anti-allodynic effects of IT gabapentin (1) .
The facilitated state evoked by formalin injection into the paw is mediated by an increase in the spinal release of glutamate and subsequent activation NMDA receptors (13) . Despite an apparent lack of gabapentin binding at the NMDA receptor ionophore (19) , d-serine, an agonist at the nonstrychnine site of the NMDA receptor, antagonizes the anticonvulsant effects of gabapentin (4) . Other studies have suggested that the anti-hyperalgesic effect of spinal gabapentin may be reversed by IT d-serine (3,15) . These results were similarly noted in the present study. In the absence of a specific binding interaction of gabapentin with the NMDA-glycine site, the relevance of this effect to the mechanism of gabapentin action is not understood.
Although the specific mechanism of gabapentin interaction is not certain, it is clear (based on binding studies) that gabapentin-like drugs (gabapentinoids) bind with high affinity at a common site and that this binding is stereospecific (19) . The stereospecificity of gabapentinoids, e.g., (ϩ) or (Ϫ) 3 isobutyl-GABA) correlates with their spinal antihyperalgesic action (3, 15) . Gabapentinoids bind with a high affinity to a subunit of a voltage-sensitive calcium channel (␣2Ѩ) (20) . Importantly, IT N-type calcium channel blockers also have an antihyperalgesic effect, as on the formalin test (21) , but these effects are accompanied by hypotension. As noted in the present study, there was no effect on blood pressure.
The practical significance of these observations is several-fold. First, they emphasize that the actions of gabapentin at the spinal level are related to the facilitated state associated with persistent afferent input. As such, this drug is an antihyperalgesic compound. Second, the ability to suppress the pain-evoked increase in blood pressure in the absence of changes in resting outflow argues that the afferent drive generated by the second phase of the formalin response is an integral component of the somatosympathetic response generated by tissue injury. Third, these data raise the question as to whether gabapentinoids may play a role as MAC-(minimum alveolar concentration of volatile anesthetics) or MACBAR-(MAC that blocks the adrenergic response) sparing drugs in surgery. MAC is commonly defined experimentally as the response evoked by an acute intense stimulus. In the case of gabapentin, this drug has no effect on the response to acute stimuli. Using an acute stimulus (tail dip), systemic gabapentin at doses that were effective as antihyperalgesic failed to be MAC-sparing with isoflurane or barbiturates (Bogue M, Yaksh T, unpublished observations). These results are thus consistent with the known properties of gabapentin action. We speculate that although the drug was ineffective in traditional MAC-sparing models, it may block the facilitatory component of somatomotor and somatosympathetic activation generated by persistent afferent input, as occurs during and after surgery. 
